+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Spine Biologics - Global Strategic Business Report

  • PDF Icon

    Report

  • 196 Pages
  • March 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 5140127

Global Spine Biologics Market to Reach $2.9 Billion by 2030

The global market for Spine Biologics estimated at US$2 Billion in the year 2022, is projected to reach a revised size of US$2.9 Billion by 2030, growing at a CAGR of 4.3% over the analysis period 2022-2030. Spinal Allografts, one of the segments analyzed in the report, is projected to record 3.9% CAGR and reach US$1.4 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Bone Graft Substitutes segment is readjusted to a revised 4.9% CAGR for the next 8-year period.

The U.S. Market is Estimated at $554.4 Million, While China is Forecast to Grow at 6.7% CAGR

The Spine Biologics market in the U.S. is estimated at US$554.4 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$593.8 Million by the year 2030 trailing a CAGR of 6.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.5% and 3.5% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 3.1% CAGR.

Select Competitors (Total 46 Featured) -

  • AlloSource
  • Alphatec Spine, Inc.
  • DePuy Synthes
  • Exactech, Inc.
  • Globus Medical, Inc.
  • Harvest Technologies
  • Medtronic, Inc.
  • NuVasive, Inc.

What's New?

  • Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
  • Global competitiveness and key competitor percentage market shares
  • Market presence across multiple geographies - Strong/Active/Niche/Trivial
  • Online interactive peer-to-peer collaborative bespoke updates
  • Access to digital archives and Research Platform
  • Complimentary updates for one year

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Spine Biologics - Global Key Competitors Percentage Market Share in 2022 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
  • Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 2: World Historic Review for Spine Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 3: World 16-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2023 & 2030
  • Table 4: World Recent Past, Current & Future Analysis for Bone Graft Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 5: World Historic Review for Bone Graft Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 6: World 16-Year Perspective for Bone Graft Substitutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 7: World Recent Past, Current & Future Analysis for Spinal Allografts by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 8: World Historic Review for Spinal Allografts by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 9: World 16-Year Perspective for Spinal Allografts by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 10: World Recent Past, Current & Future Analysis for Cell-based Matrix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 11: World Historic Review for Cell-based Matrix by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 12: World 16-Year Perspective for Cell-based Matrix by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 13: World Spine Biologics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • Table 14: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 15: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 16: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers (ASCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 18: World Historic Review for Ambulatory Surgery Centers (ASCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 19: World 16-Year Perspective for Ambulatory Surgery Centers (ASCs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2023 & 2030
III. MARKET ANALYSIS
  • UNITED STATES
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
  • Table 23: USA Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 24: USA Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 25: USA 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
  • Table 26: USA Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 27: USA Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 28: USA 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • CANADA
  • Table 29: Canada Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 30: Canada Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 31: Canada 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
  • Table 32: Canada Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 33: Canada Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 34: Canada 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • JAPAN
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
  • Table 35: Japan Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 36: Japan Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 37: Japan 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
  • Table 38: Japan Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 39: Japan Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 40: Japan 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • CHINA
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
  • Table 41: China Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 42: China Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 43: China 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
  • Table 44: China Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 45: China Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 46: China 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • EUROPE
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
  • Table 47: Europe Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 48: Europe Historic Review for Spine Biologics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 49: Europe 16-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2023 & 2030
  • Table 50: Europe Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 51: Europe Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 52: Europe 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
  • Table 53: Europe Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 54: Europe Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 55: Europe 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • FRANCE
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
  • Table 56: France Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 57: France Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 58: France 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
  • Table 59: France Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 60: France Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 61: France 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • GERMANY
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
  • Table 62: Germany Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 63: Germany Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 64: Germany 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
  • Table 65: Germany Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 66: Germany Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 67: Germany 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • ITALY
  • Table 68: Italy Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 69: Italy Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 70: Italy 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
  • Table 71: Italy Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 72: Italy Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 73: Italy 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
  • Table 74: UK Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 75: UK Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 76: UK 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
  • Table 77: UK Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 78: UK Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 79: UK 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • SPAIN
  • Table 80: Spain Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 81: Spain Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 82: Spain 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
  • Table 83: Spain Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 84: Spain Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 85: Spain 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • RUSSIA
  • Table 86: Russia Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 87: Russia Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 88: Russia 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
  • Table 89: Russia Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 90: Russia Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 91: Russia 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • REST OF EUROPE
  • Table 92: Rest of Europe Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 93: Rest of Europe Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 94: Rest of Europe 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
  • Table 95: Rest of Europe Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 96: Rest of Europe Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 97: Rest of Europe 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
  • Table 98: Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
  • Table 99: Asia-Pacific Historic Review for Spine Biologics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 100: Asia-Pacific 16-Year Perspective for Spine Biologics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2023 & 2030
  • Table 101: Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 102: Asia-Pacific Historic Review for Spine Biologics by Product - Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 103: Asia-Pacific 16-Year Perspective for Spine Biologics by Product - Percentage Breakdown of Value Sales for Spinal Allografts, Bone Graft Substitutes and Cell-based Matrix for the Years 2014, 2023 & 2030
  • Table 104: Asia-Pacific Recent Past, Current & Future Analysis for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
  • Table 105: Asia-Pacific Historic Review for Spine Biologics by End-Use - Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
  • Table 106: Asia-Pacific 16-Year Perspective for Spine Biologics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Ambulatory Surgery Centers (ASCs) and Other End-Uses for the Years 2014, 2023 & 2030
  • AUSTRALIA
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2023 (E)
  • INDIA
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2023 (E)
  • SOUTH KOREA
  • REST OF ASIA-PACIFIC
  • LATIN AMERICA
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2023 (E)
  • ARGENTINA
  • BRAZIL
  • MEXICO
  • REST OF LATIN AMERICA
  • MIDDLE EAST
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2023 (E)
  • IRAN
  • ISRAEL
  • SAUDI ARABIA
  • UNITED ARAB EMIRATES
  • REST OF MIDDLE EAST
  • AFRICA
  • Spine Biologics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2023 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AlloSource
  • Alphatec Spine, Inc.
  • DePuy Synthes
  • Exactech, Inc.
  • Globus Medical, Inc.
  • Harvest Technologies
  • Medtronic, Inc.
  • NuVasive, Inc.

Table Information